Regeneron's Pasatru Demonstrates Sustained Efficacy in Long-Term Trial for Rare Bone Disease FOP

Regeneron Pharmaceuticals announced positive 84-week results from the Phase 3 OPTIMA trial for Pasatru (garetosmab-grts) in adults with fibrodysplasia ossificans progressiva (FOP). The longer-term findings showed sustained efficacy in halting new, abnormal bone growth (heterotopic ossification lesions) and significantly reducing disease flare-ups. Pasatru was recently FDA-approved based on 56-week data for this rare, debilitating condition.